The results of our study indicate that combining FAK inhibition with erlotinib more effectively reduces EGFR wild-type NSCLC cell viability in vitro and xenograft tumor growth in vivo than either drug treatment alone, with particular efficacy in the A549 cell type. Here, EGFR is linked to neoplasm.